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INTRODUCTION
Functional gastrointestinal disorders such as the Functional bowel disorders and functional 
abdominal pain are the most common disorders encountered by the gastroenterologist and constitute a 
considerable economic burden to the health care system.1 However, the accuracy of a diagnosis based 
purely  on  the  presenting gastrointestinal  symptoms  continues  to  worry  practicing  physicians.2 
Traditionally, a diagnosis of a functional bowel disorder is based on the classical symptom patterns in 
the absence  of  an organic  explanation by appropriate  testing.  Thus functional  bowel  disorders  are 
diagnosed when unexplained  abdominal  pain and  bowel  symptoms coexist while the  role  of  other 
potential diagnostic criteria remains unclear.3 
There is a limit to the repertoire of gastrointestinal symptoms and hence it is understandable 
that symptoms alone may not be accurate enough to identify functional from organic disease. However, 
in  the  absence  of  a  reproducible  and  accepted  biological marker,  symptoms  currently  remain  the 
primary means of identifying patients in clinical practice and recruiting patients for research studies. 
Several diagnostic approaches that are based on the patient’s symptoms, such as the Manning criteria,4 
the Kruis scoring system,5 or the Rome criteria,6 have been proposed to assist the diagnostic process. 
However, the available literature suggests that symptom based diagnostic algorithms, although often 
used for clinical and research studies, have poor sensitivity.7  Although diagnostic algorithms such as 
the Manning criteria or the Rome criteria can discriminate IBS from health or upper gastrointestinal 
tract conditions, studies do not provide convincing evidence that the criteria can discriminate IBS from 
organic disease of the colon.8 Thus, in clinical practice functional gastrointestinal disorders are still 
often identified by exclusion. 
In daily clinical practice, history taking includes a search for leading symptoms, as suggested 
by diagnostic  algorithms for  functional  bowel  disorders,  as  well  as  an intensive clinical search for 
6
evidence of organic disease (alarm symptoms or features), such as older age at symptom onset, weight 
loss, gastrointestinal bleeding, etc. Current guidelines recommend a full diagnostic workup in patients 
who  present  with  such  alarm features.9 Vanner  and  colleagues10 suggested  that  evaluating alarm 
symptoms in combination with the Rome I criteria improved the predictive value for diagnosing IBS. 
However,  the value of these symptoms in discriminating organic disease from functional disorders 
remains uncertain, especially as alarm features are common, even in younger people in the general 
population.11 
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AIM OF THE STUDY
1. To assess the value of alarm features in differentiating organic disease from 
functional bowel disorders and functional abdominal pain syndrome
2. To assess the outcome of colonoscopy in diseases of the lower gastrointestinal 
tract 
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REVIEW OF LITERATURE
Throughout  recorded  history,  and  alongside  structural  diseases  of  the  intestinal  tract,  are 
maladies that have produced multiple forms of pain, nausea, vomiting, bloating, diarrhea, constipation, 
or difficult passage of food or feces. Although structural diseases can be identified by pathologists and 
at times cured by medical technology, the nonstructural symptoms that are described as “functional” 
remain enigmatic and less amenable to explanation or effective treatment. Often considered “problems 
of living,” there are physiological, intrapsychic and sociocultural factors that amplify perception of 
these symptoms so they are experienced as severe, troublesome or threatening, with subsequent impact 
on daily life activities. Those suffering from such symptoms attribute them to an illness and self treat or 
seek  medical  care.  Traditionally  trained  physicians  then  search  for  a  disease  in  order  to  make  a 
diagnosis and offer treatment specific to the diagnosis. In most cases, no structural etiology is found, 
the doctor concludes that the patient has a “functional” problem and the patient is evaluated and treated 
accordingly. 
Functional Bowel Disorders
Functional  bowel  disorders  are  functional  gastrointestinal  disorders  with 
symptoms attributable to the middle or lower gastrointestinal tract. These include the 
IBS, functional bloating, functional constipation, functional diarrhea, and unspecified 
functional bowel disorder.
To separate these chronic conditions from transient gut symptoms, they must 
have occurred for the first time  > 6 months before the patient presents, and their 
presence on > 3 days a month during the last 3 months indicates  current activity.
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Previous  diagnostic  criteria  presumed  the  absence  of  a  structural  or 
biochemical  disorder.  However,  research  will  likely  confirm  that  functional  gut 
disorders  manifest  such  findings.  Moreover,  IBS,  functional  bloating,  functional 
constipation and functional diarrhea may have multiple etiologies.
 
The functional bowel disorders are classified into
C. Functional bowel disorders
C1. Irritable bowel syndrome 
C2. Functional bloating 
C3. Functional constipation 
C4. Functional diarrhea
C5. Unspecified functional bowel disorder
 
C1. Irritable Bowel Syndrome 
Definition  
IBS is a functional bowel disorder in which abdominal pain or discomfort is 
associated with defecation or a change in bowel habit, and with features of disordered 
defecation.
Epidemiology
Throughout  the  world,  abort  10%  -  20%  of  adults  and  adolescents  have 
symptoms consistent with IBS, and most studies find a female predominance.12 IBS 
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symptoms come and go over time, often overlap with other functional disorders,13 
impair quality of life,14 and result in high health care costs.15 
C1. Diagnostic criteria* for irritable bowel syndrome
   Recurrent abdominal pain or discomfort** at least 3 days per month in the last 3 
months associated with 2 or more of the following:
1. Improvement with defecation
2. Onset associated with a change in frequency of stool 
3. Onset associated with a change in form (appearance) of stool
* Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to 
diagnosis.
**  Discomfort  means  an  uncomfortable  sensation  not  described  as  pain.  In 
pathophysiology research and clinical trials, a pain/discomfort frequency of at least 2 
days a week during screening evaluation for subject eligibility.
Supportive  symptoms  that  are  not  part  of  the  diagnostic  criteria  include 
abnormal  stool  frequency ([a]  ≤  3 bowel  movements  per  week or  [b]  >  3  bowel 
movements per day), abnormal stool form ([c] lumpy/hard stool or [d] loose/ watery 
stool),  [e]  defecation straining,  [f]  urgency,  or also a feeling of incomplete  bowel 
movement, passing mucus, and bloating.
The Rome II working team suggested 2 systems for classifying patients into 
diarrhea – predominant and constipation – predominant subgroups based on the first 6 
of these features.16,17 The Rome II book classification based on the first 6 supportive 
symptoms includes: diarrhea predominant: 1 or more of b, d, f, and none of a, c, e, or 
≥2 of b, d, f, or ≥ 2 of a, c,e, and 1 of b, d, f.  
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Both variations exclude patients with hard stools from the diarrhea subtype, 
but 1 version can include patients with watery stools in the constipation subgroup. 
Investigators have used these methods and modifications of them to select patients for 
treatment trials targeting a specific bowel pattern.  
Sub typing IBS by predominant stool pattern
1. IBS  with  constipation  (IBS-C)  –  hard  or  lumpy  stools  ≥25%  and  loose 
(mushy) or watery stools < 25% of bowel movements.
2. IBS with diarrhea (IBS-D)- loose (mushy or watery stools ≥25% and hard or 
lumpy stool <25% of bowel movements.
3. Mixed IBS (IBS-M) – hard or lumpy stools  ≥25% and loose (mushy)  or 
watery stools ≥25% of bowel movements.
4. Unsubtyped  IBS  –  insufficient  abnormality  of  stool  consistency  to  meet 
criteria for IBS-C, D, or M.
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Patient reports of “diarrhea” and “constipation” may mislead physicians. The 
stool  may  be  solid,  though  defecation  is  frequent  (pseudodiarrhea).18 Conversely, 
straining  to  defecate  may  occur  with  soft  or  watery  stools.  Some  patients  feel 
constipated  because  they  have  unproductive  urges  to  defecate  or  feelings  of 
incomplete evacuation that prompt them to strain after passing stool. The need for 
accurate symptom description is corroborated by reports of straining, urgency, and 
incomplete evacuation across the spectrum of stool form.19 In subgroups identified by 
cluster analysis or symptoms, most patients have a stool frequency within the normal 
range regardless of bowel pattern. However, stool form (from watery to hard) reflects 
intestinal transit time. 
Researchers and practitioners use the Bristol  stool form scale18 (table 3) to 
identify constipation as types 1 and 2 and diarrhea as types 6 and 7.
The Bristol stool form scale
Type                                          Description 
1                 Separate hard lumps like nuts (difficult to pass)
2                 Sausage shaped but lumpy 
3                 Like a sausage but with cracks on its surface 
4                 Like a sausage or snake, smooth and soft
5                 Soft blobs with clear-cut edges (passed easily)
6                 Fluffy pieces with ragged edges, a mushy stool
7                 Watery, no solid pieces, entirely liquid
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Rationale for changes in the diagnostic criteria
        The symptom criteria are useful for clinical practice, epidemiologic surveys, 
pathophysiology research, and therapeutic trials. The symptom frequencies suggested 
for  the  FBDs  are  arbitrary  and  may  need  to  be  modified  for  different  purposes. 
Epidemiologists should explore several frequencies to understand their significance. 
In  therapeutic  trials,  the  higher  the  symptom  frequency  threshold  for  subject 
enrollment, the larger the potential treatment effect and the smaller the number of 
subjects that may be needed to show a significant difference. However, such patients 
may be less likely to achieve satisfactory relief, and such studies are less applicable to 
the  general  population.  Hence,  enrollment  symptom  criteria  are  critical.  The 
recommended  threshold  for  pain  or  discomfort  of   ≥  2  days  a  week  for 
pathophysiology studies and clinical trials is reported by a majority of IBS patients.20 
About  three  fourths  of  patients  who  rated  their  pain  as  at  least  moderate  (not 
ignorable, but without affect on lifestyle) also had pain ≥2 days a week.21 Because 
relief  of  pain/discomfort  with  defecation  may  be  incomplete,  improved with 
defecation replaces relieved.
The Rome II sub typing using multiple criteria were complex and difficult to 
use in practice. We therefore simplified them by using only the most reliable criterion, 
stool  form.  Current  evidence  indicates  that  bowel  pattern  sub typing  is  best  done 
according to stool form rather than bowel frequency, particularly IBS-M; however, 
we emphasize that bowel pattern subtypes are highly unstable. In a patient population 
with  approximately  33% prevalence  rates  of  IBS-D,  IBS-C,  and  IBS-M,  75% of 
patients  change subtypes  and 29% switch  between IBS-C and IBS-D over1  year. 
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Other  investigators  report  the  IBS-M  subtype  in  about  50%  of  referred  patients 
according to 3 sets of criteria, and IBS-M is the most prevalent group in primary care. 
In addition, a majority of patients have rapidly fluctuating symptoms lasting from <1 
hour  to  <1  week.  Therefore,  the  rate  of  documented  bowel  pattern  change  is  a 
function of the data collection frequency, and   there are insufficient data upon which 
to recommend a time period for defining IBS-A. In drug studies on patients sub typed 
by  stool  form,  investigators  may  want  to  assess  pharmacologic  effects  on  stool 
frequency,  straining,  urgency  and  incomplete  evacuation  as  well  as  stool  form. 
Although the committee recommends a change in sub typing from the multi symptom 
Rome II classification to one based on stool form only, there are insufficient data to 
exclude either classification at this time. Further validation studies are needed.
Because of the characteristic symptom instability,  we prefer the terms IBS 
with  constipation  and  IBS  with  diarrhea  instead  of  constipation  and  diarrhea 
predominant IBS. In this categorical system, many people whose features place them 
close  to  a  subtype  boundary  change  pattern  without  a  major  change  in 
pathophysiology.  Moreover, the heterogeneity and variable natural history of IBS 
significantly limit clinical trials of motility-active drugs and drug therapy in practice. 
In both research and practice, it may be desirable to base drug use on a stronger bowel 
pattern predominance than the requirements of this system.
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Clinical Evaluation
        Diagnosis depends on careful interpretation of the temporal relationships of pain/
discomfort,  bowel  habit,  and  stool  characteristics.  Pain/discomfort  related  to 
defecation  is  likely to  be  of  bowel  origin,  whereas  that  associated  with  exercise, 
movement,  urination,  or  menstruation  usually  has  a  different  cause.  Fever, 
gastrointestinal  bleeding,  weight  loss,  anemia,  abdominal  mass,  and other  ”alarm” 
symptoms or signs are not due to IBS, but may accompany it.
In  women,  so-called  pelvic  pain,22 worsening  of  IBS  symptoms  during 
menstruation,  and  dyspareunia  or  other  gynecologic  symptoms  may  obscure  the 
diagnosis.
Incorrect  symptom  attribution  can  lead  to  hospitalization  and  surgery; 
especially cholecystectomy, appendectomy, and hysterectomy. The recognition and 
evaluation of  bowel  dysfunction  in  patients  with  “pelvic” or  abdominal  pain may 
reduce unnecessary surgery.
   Heartburn,  fibromyalgia,  headache,  backache,  genitourinary symptoms,  and 
others  are  often  associated  with  IBS,  but  are  not  useful  in  diagnosing  it.  These 
symptoms  increase  as  the  severity  of  IBS  increases  and  may be  associated  with 
psychological factors. Obviously, a common disorder such as IBS may coexist with 
organic gastrointestinal disease. There are no discriminating physical signs of IBS, 
but abdominal tenderness may be present. Tensing the abdominal wall increases local 
tenderness associated with abdominal wall pain, whereas it lessens visceral tenderness 
by protecting the abdominal organs (Carnet test).23
        Few tests are required for patients who have typical IBS symptoms and no alarm 
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features.24 Unnecessary investigations  may be costly and even harmful.  Testing is 
based on the patient’s age, duration and severity of symptoms, psychosocial factors, 
alarm symptoms and family history of gastrointestinal  disease.  Investigations  may 
include  a  sigmoidoscopy  or  colonoscopy  to  rule  out  inflammation,  tumors,  or 
melanosis  coli  owing to  regular  laxative  use.  Stool  examination  for  occult  blood, 
leukocytes,  or  ova  and  parasites  (e.g.,  giardia)  where  they  are  endemic  may  be 
indicated, but routine rectal biopsy and abdominal ultrasonography usually are not. 
Many people  who  report  severe  lactose  intolerance  absorb  lactose  normally  with 
negligible symptoms, undermining the value of documenting lactase deficiency. The 
discovery of diverticulosis does not change the diagnosis of IBS.25 Some patients with 
celiac sprue have IBS symptoms. In IBS patients who were HLA-DQ2-positive and 
had intestinal  antibodies to gliadin and other dietary proteins, stool frequency and 
intestinal IgA levels decreased after gluten restriction. However, the available data 
suggest  testing  for  celiac  disease  only  if  indicated  by  clinical  features  and  local 
prevalence.
A confident diagnosis that holds up over time can usually be made through 
careful history taking, examination, and limited laboratory and structural evaluations 
individualized  to  each  patient’s  needs.  IBS  is  often  properly  diagnosed  without 
testing.  After  diagnosis,  a  change  in  the  clinical  features  may warrant  additional 
investigation.  However,  persistence  and  recurrence  is  expected,  and  needless 
investigation  may undermine  the  patient’s  confidence  in  the  diagnosis  and  in  the 
physician.
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Physiologic Features
        IBS is best viewed as an interaction of important biological and psychosocial 
factors. Altered motility, visceral hyperalgesia, disturbance of brain-gut interaction, 
abnormal  central  processing,  autonomic  and  hormonal  events,  genetic  and 
environmental  factors,  post  infectious  sequels,  and  psychosocial  disturbance  are 
variably involved, depending on the individual.26
Psychosocial Features
         Psychological disturbance, especially in referred patients, includes psychiatric 
disorders  (e.g.,  panic  disorder,  generalized  anxiety  disorder,  mood  disorder,  and 
posttraumatic stress disorder), sleep disturbance, and dysfunctional coping. A history 
of childhood abuse is common.27 Although stressful life events sometimes correlate 
with symptom exacerbation, the nature of the link between psychosocial factors and 
IBS is unclear.
Treatment 
      Management depends on a confident diagnosis, explanation of why symptoms 
occur,  and  suggestions  for  coping  with  them.  Education  about  healthy  lifestyle 
behaviors, reassurance that the symptoms are not due to a life-threatening disease 
such  as  cancer,  and  establishment  of  a  therapeutic  relationship  are  essential,  and 
patients have a greater expectation of benefit from lifestyle modification than drugs.28 
For such counseling, individual or group interactions are effective.
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          Most IBS patients present to primary care where physicians are best positioned 
to  know  their  histories,  personalities,  and  families.  Specialists’  patients  are  more 
likely to  have severe  symptoms,  depression,  anxiety,  panic,  or  other  complicating 
psychosocial  disorders  that  require  special  treatment.  In  addition  to  allaying  fear, 
physicians should recover any unstated worries or aggravating factors. It is important 
to assess the patient’s quality of life and level of daily functioning, personality, recent 
life stress (e.g., divorce, bereavement, or job loss), and any psychological disturbance.
              The type and severity of symptoms and the nature of associated psychosocial 
issues determine treatment.29 Psychological  factors  may alter  symptom perception, 
and the patient’s reaction to the symptoms may be more important than the symptoms 
themselves. Most patients respond to psychological support, a strong physician patient 
relationship,  and  multicomponent  treatment  approaches  that  reduce  health  care 
utilization.  The  physician  should  be  understanding,  maintain  patient  contact,  and 
prevent over testing and harmful treatments. Unsatisfied patients may consult many 
physicians,  undergo  unjustified  and  hazardous  investigation,  take  unproven 
medication, and have unneeded surgery.
              Patients should avoid nutritionally depleted diets and have regular, unhurried 
meals.  Lactose restriction usually fails  to  improve symptoms,  and dietary calcium 
restriction  may  be  harmful.  Excessive  fructose  and  artificial  sweeteners,  such  as 
sorbitol or mannitol, may cause diarrhea, bloating, cramping, or flatulence. More data 
are  necessary  before  testing  for  1gG  antibodies  to  certain  foods  can  be 
recommended.30 Dietary fiber  for  IBS is  time honored,  inexpensive,  and safe,  but 
poorly substantiated by clinical trials. Indeed, many patients believe bran exacerbates 
their symptoms, and the only substantial randomized controlled trial of bran suggested 
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it exacerbated flatulence and did not relieve pain. 
Possible drugs for a dominant symptom in IBS
Symptom                    Drug                                Dose
Diarrhea Loperamide                  2-4 mg when necessary/maximum 12g/d
                               Cholestyramine resin    4g with meal 
                                Alosetron                     0.5-1 mg bid (for severe IBS, women)
Constipation          Psyllium husk                3.4 g bid with meals, then adjust
                                 Methylcellulose              2g bid with meals, then adjust
                                 Calcium polycarbophil   1g qd to qid
                                  Lactulose syrup                 10-20g bid
                                  70% sorbitol                     15 ml bid
                                   Polyethylene glycol  3350  17g in 8 oz water qd
                                    Tegaserod                        6mg bid (for IBS, women)
                                   Magnesium hydroxide      2-4 tbsp qd                                         
Abdominal pain      Smooth-muscle relaxant    qd to qid ac 
                                   Tricyclic antidepressants    start 25-50 mg hs, then adjust
                                  Selective serotonin              begin small dose, increase
                                     reuptake inhibitors            as needed
         Drug therapy is directed toward the dominant symptoms. Their changeable 
nature and the complex interactions between the central and enteric nervous systems 
circumscribe  the  effectiveness  of  specific  therapies.  Researchers  are  searching  for 
biomarkers  and genetic  polymorphisms that  might  identify patients  most  likely to 
respond to drugs. Early therapeutic trials had significant methodological inadequacies, 
and  deficiencies  and publication bias  persist.  Drugs  help only some symptoms in 
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selected patients. Loperamide may prevent diarrhea when taken before a meal or an 
activity that often leads to the symptom. Constipation is treated initially with dietary 
fiber supplementation. If response is unsatisfactory,  commercial fiber analogs may 
help.  The  heterogeneous  smooth-muscle  relaxants  are  questionably  beneficial  for 
pain; trial deficiencies leave their efficacy in doubt.31 Furthermore, their availability 
varies  in  Australia,  Canada,  Europe,  and  the  United  States.  Antidepressant  drug 
therapy in lower than antidepressant doses may be beneficial even if there is no major 
psychiatric co morbidity. For example, desipramine benefits women with moderate to 
severe IBS who do not discontinue the drug owing to  side effects,  and the effect 
appears unrelated to the drug dose. Paroxetine improves the physical component of 
quality of life of patients with severe IBS and is more effective than a high-fiber diet 
in  improving  global  status.  The  narrow  therapeutic  window  for  antidepressants 
suggests they be limited to patients with moderate or severe IBS.
            Alosetron, a selective serotonin 5-HT3 receptor antagonist, can decrease pain, 
urgency, stool frequency, and increase global status in women with diarrhea and IBS. 
Based on rigorous studies, the number needed to treat (NNT) is 7.32 Ischemic colitis 
and severe obstipation led to its withdrawal, but it was reintroduced only in the United 
States with restricted access and a risk management program. It was efficacious and 
safe in a 48- week trial. Well-designed studies of tegaserod, a partial 5-HT4 receptor 
agonist,  found  it  can  improve  overall  status,  stool  frequency  and  form,  ease  of 
evacuation, and bloating in women with IBS and constipation. In 8 studies, the NNT 
for daily doses of 12mg and 4mg was 14 and 20, respectively, and it is as effective in 
re treating patients as during initial therapy. Published trials comparing alosetron and 
tegaserod  with  conventional  anti  diarrheals  and  laxatives,  respectively,  are  not 
available,  and interpretation of NNT values calculated from older studies of these 
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agents is compromised by trial deficiencies.
              Preliminary trials of probiotics are encouraging,  especially symptom 
improvement  and  normalization  of  the  blood  mononuclear  cell  ration  of  an  anti-
inflammatory  to  a  pro  inflammatory  cytokine  in  patients  taking  bifidobacterium 
infantis, but these studies need repeating in larger numbers of patients before they can 
be considered established treatments. Small bowel bacterial overgrowth, as diagnosed 
by lactulose hydrogen breath testing is a suggested but disputed cause of IBS, and 
antibiotics  provide  only  transient  benefit  and  risk  clostridium  difficile  infection, 
allergic reactions, anti microbial resistance, and chronic functional symptoms.
      Cognitive- behavioral therapy, standard psychotherapy, and hypnotherapy may 
help selected IBS patients. Weekly cognitive- behavioral therapy for 12 weeks was 
better  than  weekly  educational  sessions,  but  depressed  patients  did  not  respond; 
quality of life but not pain, improved. Hypnotherapy, the most thoroughly evaluated 
psychological treatment, normalizes rectal sensation, 33 and 12 sessions benefit quality 
of  life,  anxiety,  and  depression  in  refractory  patients  (except  men  with  IBS  and 
diarrhea),  and the benefits  last ≥5 years.  However,  trials  of psychological  therapy 
cannot  be  double  blind,  and  treatment  is  time  consuming,  costly,  and  often 
unavailable.  
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C2.Functional Bloating
Definition 
       Functional bloating is a recurrent sensation of abdominal distention that may or 
may not be associated with measurable distention, but is not part of another functional 
bowel or gastro duodenal disorder.
Epidemiology         
        Most of the research on bloating has dealt with subjects who also have other 
functional gastrointestinal disorders; up to 96% of IBS patients report this symptom. 
Community surveys reveal that about 10%-30% of individuals report bloating during 
the  previous  year.  It  is  about  twice  as  common in  women  as  men,  and  is  often 
associated with menses. Typically, it worsens after meals and throughout the day and 
improves or disappears overnight. Abdominal inductance plethysmography confirms 
increased abdominal girth in some bloated IBS patients.34
C2. Diagnostic criteria* for functional bloating 
Must include both of the following:
1. Recurrent feeling of bloating or visible distention at least 3 days/month in 3 months
2. Insufficient criteria for a diagnosis of functional dyspepsia, IBS, or other functional 
GI disorder
*Criteria  fulfilled  for  the last  3  months  with  symptom onset  at  least  6  months  prior  to 
diagnosis
Rationale for the criteria
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           Because abdominal as a modifier of  bloating is redundant, it was omitted. 
Fullness  was also deleted,  because it  may imply postprandial  satiety,  yet  bloating 
occurs  throughout  the  day.  Importantly,  bloating  overlaps  with  other  functional 
disorders (e.g., functional constipation, IBS, and functional dyspepsia), epidemiologic 
surveys and factor analyses do not convincingly demonstrate a distinct bloating group, 
and  physiologic  studies  of  bloating  have mainly been done on patients  with IBS. 
Because of the lack of data on bloating frequency, the frequency criterion is arbitrary 
and  may  need  to  be  modified  for  different  purposes.  Additional  epidemiologic 
research should investigate functional bloating.
Clinical evaluation
            Bloating is distinguished from other causes of abdominal distention by its 
diurnal pattern. It may follow ingestion of specific food. Excessive burping or flatus is 
sometimes present, but these may be unrelated to the bloating. Diarrhea, weight loss, 
or nutritional deficiency should prompt investigation for intestinal disease.
Physiologic features
No unified pathophysiologic mechanism can be applied to all patients. Food 
intolerance, abnormal gut bacterial flora, weak abdominal musculature, and abnormal 
retention of fluid inside and outside the gut do not appear to be significant factors. 
However, studies have documented both increased intestinal gas accumulation and 
abnormal gas transit. Visceral hyperalgesia may be important in some patients.
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Psychosocial features
        No uniform psychological factors have been identified.
Treatment 
           Although the functional bloating criteria require the absence of other disorders, 
most research has been done on patients who have IBS or another disorder; therefore, 
treatment  of  bloating  is  similar  whether  it  is  isolated  or  associated  with  another 
functional disorder. Most treatments are designed to reduce flatus or gut gas, which 
are of unproved importance in bloating, and most are of unproven efficacy. Bloating 
may decrease if an associated gut syndrome such as IBS or constipation is improved. 
If bloating is accompanied by diarrhea and worsens after ingesting dairy products, 
fresh  fruits,  or  juices,  further  investigation  or  a  dietary  exclusion  trial  may  be 
worthwhile. However, even patients with proven lactase deficiency experience little 
or no bloating after drinking 240 mL of milk. Avoiding flatogenic foods, exercising, 
losing excess weight, and taking activated charcoal are safe but unproven remedies.35 
Data regarding the use of surfactants such as simethicone are conflicting. Antibiotics 
are  unlikely to  help,  but  trials  of  probiotics  are  encouraging.  Beano,  an over-the-
counter  oral  ß-glycosidase  solution,  may  reduce  rectal  passage  of  gas  without 
decreasing bloating and pain.36 Pancreatic enzymes reduce bloating, gas, and fullness 
during and after high-calorie, high-fat meal ingestion. Tegaserod improves bloating (a 
secondary outcome measure) in some constipated female IBS patients.
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C3. Functional constipation
Definition 
          Functional  constipation  is  a  functional  bowel  disorder  that  presents  as 
persistently difficult,  infrequent, or seemingly incomplete defecation, which do not 
meet IBS criteria.
              Subjective and objective definitions of constipation include straining, hard 
stools or scybala (hard, inspissated stool), unproductive calls (“want to but cannot”), 
infrequent stools,  or  incomplete evacuation; >3 bowel movements per week, daily 
stool weight <35 g/day, or straining >25% of the time; and prolonged whole gut or 
colonic transit.  Stool frequency correlates poorly with colonic transit,  but one can 
estimate  gut  transit  using  the  Bristol  stool  form  scale.  Usually,  there  is  no 
demonstrable physiological abnormality.
Epidemiology 
          Constipation occurs in up to 27% of people depending on demographic factors, 
sampling, and definition. It affects all ages and is most common in women and non-
whites. In 1 survey, the prevalence was sought by 3 means: patient complaint, Rome I 
Criteria,  and  transit  time37 (using  the  Bristol  scale).  Approximately  8%  had 
constipation by each definition, but only 2% were constipated by all 3. Therefore, the 
concept of constipation is complicated by disagreement among patients and doctors 
about its nature. 
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C3. Diagnostic criteria* for functional constipation
1. Must include 2 or more of the following:
a. Straining during at least 25% of defecations
b. Lumpy or hard stools in at least 25% of defecations
c. Sensation of incomplete evacuation for at least 25% of defecations
d. Sensation of anorectal obstruction / blockage for at least 25% of defecations
e. Manual  maneuvers  to  facilitate  at  least  25%  of  defecations  (e.g.,  digital  evacuation, 
support of the pelvic floor)
f. Fewer than 3 defecations per week 
2. Loose stools are rarely present without the use of laxatives 
3. There are insufficient criteria for IBS
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months prior to diagnosis
Rationale for changes to diagnostic criteria
            A required frequency of “≥25%” is substituted for “>25%” to maintain 
consistency with other  FBD criteria.  Studies using Rome II  criteria  yield a  lower 
prevalence than those using Rome I criteria because the Rome II criteria did not allow 
for laxative-induced loose stools, an anomaly that is corrected in the Rome III criteria.
Clinical evaluation 
          The physician should clarify what the patient means by constipation. Manual 
maneuvers  to  assist  defecation  or  straining  to  expel  soft  stools  suggest  anorectal 
dysfunction, but are diagnostically unreliable.38 Transit time can be estimated using 
the  Bristol  scale.  Evaluation  of  the  patient’s  gut  symptoms,  general  health, 
psychological status, use of constipating medications, dietary fiber intake, and signs 
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of  medical  illnesses  (e.g.,  hypothyroidism)  should  guide  investigation.  Physicians 
should perform perianal and anal examination to detect fecal impaction, anal stricture, 
rectal prolapse, mass, or abnormal perineal descent with straining. Laboratory tests 
are rarely helpful. Endoscopic evaluation of the colon may be justified for patients 
>50 years with new symptoms or patients with alarm features or a family history of 
colon cancer.
           If  fiber  supplementation  fails  to  help  or  worsens  the  constipation, 
measurements of whole gut transit time may identify cases of anorectal dysfunction or 
colon inertia. Using radio opaque markers,  measurement of whole gut transit  time 
(primarily colon transit) is inexpensive, simple, and safe. Several methods produce 
similar  results.  Retention of markers in  the proximal  or transverse colon suggests 
colonic  dysfunction,  and  retention  in  the  recto  sigmoid  area  suggests  obstructed 
defecation. A radioisotope technique involves less radiation than plain x-rays and may 
provide  more  information,  helping  to  differentiate  proximal  colon  emptying, 
pancolonic inertia, and dyssynergic defecation.
Physiologic Factors
       Severe,  intractable  constipation  may be due  to  colonic  inertia  or  anorectal 
dyssynergia.  These  disorders  may  coexist,  but  most  patients  complaining  of 
constipation have normal colonic transit and anorectal function.
Psychosocial Factors 
            No uniform psychological profile is applicable to patients with constipation; 
however, patients  with severe constipation and normal intestinal  transit  often have 
28
increased psychological distress, and depressed patients may have constipation.
Treatment 
         Reassurance may convince some patients that failure to evacuate for 2 or 3 days 
is  harmless.  Increased fluid intake and physical  exercise  are  unproven measures.39 
Physicians  should  stop or  reduce  any constipating  medication  the  patient  may be 
taking and treat depression and hypothyroidism when present. Pharmacologic therapy 
is  not  advisable  until  general  and  dietary measures  are  exhausted.  There  are  few 
published trials of some commonly used medical therapies.
           The severity and nature of the symptoms guide further treatment.  The 
indigestible  matter  in  dietary  fiber  increases  fecal  bulk  by promoting  fecal  water 
holding capacity and bacterial proliferation. Other bulking agents include psyllium, 
methylcellulose, and calcium polycarbophil. Although stimulating laxatives such as 
bisacodyl, sodium picosulphate, or sennosides may be tried, their effectiveness and 
long-term safety have not been determined by placebo – controlled trials; they were 
introduced in an era when high quality trials were not performed. Polyethylene glycol 
solution, lactulose, and sorbitol may be useful. Tegaserod is superior to placebo for 
patients with chronic constipation.40 Recent studies suggest that prostaglandin analogs 
may be helpful. 
C4. Functional diarrhea 
Definition 
         Functional diarrhea is a continuous or recurrent syndrome characterized by the 
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passage of loose (mushy) or watery stools without abdominal pain or discomfort.
Epidemiology           
           There are few studies in which functional diarrhea was specifically diagnosed 
as distinct from IBS-D, so it is impossible to provide a precise frequency. 9.6% of 
Minnesota  residents  and  4.8%  of  people  throughout  the  United  States  reported 
unspecified diarrhea; however, its duration and frequency are uncertain. Although a 
common  reason  for  consulting  a  gastroenterologist,  diarrhea  was  a  presenting 
complaint of <2% of general practice patients.
C4. Diagnostic criterion* for functional diarrhea
Loose (mushy) or watery stools without pain occurring in at 
least 75% of stools 
*Criterion fulfilled for the last 3months with symptom onset at  
least 6 months before diagnosis 
  
Rationale for the criteria 
         Most people apply the term diarrhea to loose or watery stools. Fewer individuals 
relate  it  to  increased  frequency  and  urgency.  Because  rapid  transit  increases  the 
percentage of water in stool, stool form correlates well with transit. Safe stools are 
85%  water,  and  watery  stools  90%  with  greatly  reduced  stool  viscosity.41 Stool 
viscosity is critical because watery stool is difficult to retain, and anal contact with 
fluid causes extreme urgency. However, urgency alone unreliably indicates diarrhea 
and may be reported by individuals with hard, pellet like stools. Thus, stool form, not 
frequency,  defines  diarrhea.  How  often  a  symptom  must  occur  to  be  significant 
depends  on  its  troublesomeness.  Just  1  episode  of  fecal  incontinence  is  a  serious 
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problem for a patient, whereas an occasional loose stool may not be.
Clinical Evaluation 
          The combination of abdominal pain with intermittent diarrhea and constipation 
is  highly  suggestive  of  IBS,  and  small-volume,  frequent  defecation  is  likely 
functional. Pseudodiarrhea (frequent defecation and urgency with solid stools) is not 
diarrhea. A stool diary incorporating the Bristol stool form scale is a useful method to 
verify stool form. Dietary history can disclose poorly absorbed carbohydrate intake, 
such as lactose by patients with hypolactasia, or “ sugar-free” products containing 
fructose, sorbitol, or mannitol. Alcohol can cause diarrhea by impairing sodium and 
water absorption from the small bowel. Physical examination should seek signs of 
anemia or malnutrition. An abdominal mass suggests crohn’s disease in the young 
patient and cancer in the elderly patient. Rectal examination, colon endoscopy, and 
biopsy can exclude villous adenoma,  microscopic colitis,  and inflammatory bowel 
disease.
            Abnormal results of blood or stool tests or other alarm features necessitate 
further  tests.  Features  of  malabsorption  (malnutrition,  weight  loss,  non-blood-loss 
anemia, or electrolyte abnormalities) should provoke the appropriate antibody tests 
and /or duodenal biopsy for celiac disease.  Where relevant,  giardiasis and tropical 
sprue should be excluded. Barium small bowel radiography may be necessary. Rarely, 
persistent diarrhea may require tests for bile acid malabsorption or, more practically, a 
trial of the bile acid-binding resin cholestyramine.
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Physiologic factors 
            Few studies have addressed the physiology of functional diarrhea. One such 
study  found  decreased  non-propagating  colonic  contractions  and  increased 
propagating colonic contractions.  
Psychosocial factors
                Psychosocial factors have also received little research attention apart from 
the finding of accelerated colonic transit inducible by acute stress.
Treatment
        Discussion  of  possible  psychosocial  factors,  symptom  explanation,  and 
reassurance is  important.  Restriction of foods such as those containing sorbitol  or 
caffeine,  which  seem  provocative,  may  help.  Empiric  antidiarrheal  therapy  (e.g., 
diphenoxylate or loperamide) is usually effective, especially if taken prophylactically, 
such as before meals or public engagements.42 Alosetron slows transit and reduces the 
gastrocolonic response in normal volunteers and may improve diarrhea. However, it is 
expensive and of limited availability only in the United States; there are no published, 
randomized, controlled trials in patients with functional diarrhea. Cholestyramine, an 
ion-exchange resin that  binds bile  acids and renders them biologically inactive,  is 
occasionally very effective. The prognosis of functional diarrhea is uncertain, but it is 
often self-limited.
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C5. Unspecified functional bowel disorder
                 Individual symptoms discussed in the previous sections are very common 
in  the  population.  These  occasionally  lead  to  medical  consultation,  yet  are 
unaccompanied  by  other  symptoms  that  satisfy  criteria  for  a  syndrome.  Such 
symptoms are best classified as unspecified.
C5. Diagnostic criterion* for unspecified functional bowel disorder
 Bowel symptoms not  attributable to and organic  etiology that  do not 
meet criteria for the previously defined categories
* Criterion fulfilled for the last 3 months with symptom onset at least 6 
months before diagnosis 
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Functional abdominal pain syndrome
Functional  abdominal  pain  syndrome  (FAPS)  represents  a  chronic  pain 
disorder localized to the abdomen with features that differentiate it from other painful 
functional gastrointestinal disorders. Like other functional gastrointestinal disorders, 
symptoms are not explainable by a structural or metabolic disorder by using currently 
available  diagnostic  methods.  FAPS  appears  highly  related  to  alterations  in 
endogenous  pain  modulation  systems,  including  dysfunction  of  descending  pain 
modulation  and  cortical  pain  modulation  circuits.  There  is  only  1  recognized 
diagnosis in this category of functional gastrointestinal disorders 
D. Functional abdominal pain syndrome
Definition 
            FAPS represents a pain syndrome attributed to the abdomen that is poorly 
related to gut function, is associated with some loss of daily activities, and has been 
present  for  at  least  6  months.  The  pain  is  constant,   nearly  constant,  or  at  least 
frequently  recurring.  The  principal  criterion  differentiating  FAPS  from  other 
functional  gastrointestinal  disorders,  such  as  irritable  bowel  syndrome  (IBS)  and 
functional dyspepsia, is the lack of symptom relationship to food intake or defecation. 
FAPS commonly is associated with a tendency to experience and report other somatic 
symptoms  of  discomfort,  including  chronic  pain  thought  to  be  related  to  the 
gynecologic or urinary systems. Psychological disturbances are more likely when pain 
is persistent over a long period of time, is associated with chronic pain behaviors, and/
or dominates the patient’s  life.  In psychiatric  nosology,  FAPS would qualify as a 
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somatoform  pain  disorder  and  satisfy  a  pain  criterion  toward  the  diagnosis  of 
somatization disorder.
Epidemiology 
        The epidemiology of FAPS is incompletely known because of limited available 
data  and  methodological  difficulties  in  establishing  a  diagnosis  that  can  be 
differentiated from other more common functional gastrointestinal disorders, such as 
IBS and functional dyspepsia, however, it is generally considered that FAPS is a less 
common  functional  disorder  than  either  IBS  or  functional  dyspepsia.  Reported 
prevalence figures in North America range from 0.5% to 2% and do not differ from 
those reported in other countries. The disorder is more common in women43 (female: 
male=3:2), with prevalence peaking in the fourth decade of life. Patients with FAPS 
have high work absenteeism and health care utilization and, thus, impose a significant 
economic burden.
D. Diagnostic criteria* for functional abdominal pain syndrome must include all 
of the following:
1. Continuous or nearly continuous abdominal pain
2. No or only occasional relationship of pain with physiological events (e.g., 
eating, defecation, or menses)
3. Some loss of daily functioning 
4. The pain is not feigned (e.g., malingering)
5. Insufficient  symptoms  to  meet  criteria  for  another  functional 
gastrointestinal disorder that would explain the pain 
*Criteria fulfilled for the last 3 months with symptom onset at least 6 months 
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before diagnosis
Rationale for changes from previous criteria 
          Studies  determining  the  reliability  of  these  criteria  in  identifying  a 
homogeneous population are lacking, and subjects with various different explanations 
for pain (in particular, chronic pain attributed to pelvic viscera) may be represented.44 
A lack of relationship of pain in FAPS with defecation separates this diagnosis from 
the  functional  bowel  disorders,  but  the  distinction  from  IBS  has  acknowledged 
difficulties and is not clearly based on scientific evidence. The requirements for some 
loss of daily functioning and that pain is not feigned are derived from the diagnostic 
criteria for somatization disorder and undifferentiated somatoform disorder. Qualifiers 
in the criteria (e.g., “occasional” and “some”) remain subjectively defined. Although 
discussed in the context of this article as a functional gastrointestinal disorder, FAPS 
also  would  qualify  as  a  pain  symptom  contributing  toward  these  diagnoses  in 
psychiatric nosology.
Clinical evaluation 
          A host of disorders can produce chronic abdominal pain, and the clinician 
should be aware of the extended differential diagnosis. Algorithms to diagnose and 
treat FAPS are empirical because objective scientific evidence to support a singular 
approach does not exist. It is suggested that evaluation consist of a clinical/psycho 
social  assessment,  observation  of  symptom  reporting  behaviors  and  a  detailed 
physical examination. By answering a few questions, the physician effectively can 
appraise the clinical features of FAPS identify the key psychosocial contributions to 
the disorder, and increase confidence in the diagnosis.45
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Symptom-related behaviors often seen in patients with 
FAPS
Expressing pain of varying intensity through verbal and nonverbal  
methods,  may  diminish  when  the  patient  is  engaged  in  
distracting  activities,  but  increase  when  discussing  a  
psychologically  distressing  issue  or  during  examination 
Urgent reporting of intense symptoms disproportionate to available 
clinical and laboratory data (eg, always rating the pain as  
“10” on a scale from 1 to 10)
Minimizing or denying a role for psychosocial contributors, or of  
evident  anxiety  or  depression,  or  attributing  them to  the  
presence  of  the  pain  rather  than  to  understandable  life  
circumstances
Requesting  diagnostic  studies  or  even  exploratory  surgery  to  
validate the condition as “organic”
Seeking health care frequently
Taking limited personal responsibility for self-management, while  
placing  high  expectations  on  the  physician  to  achieve  
symptom relief
Making  requests  for  narcotic  analgesics  when  other  treatment  
options been implemented
Typically,  FAPS patients  describe abdominal  pain  in  emotional  terms,46 as 
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constant and not influenced by eating or defecation, as involving a large anatomic 
area rather than a precise location, as one of several other painful symptoms, and as a 
continuum of painful experiences beginning in childhood or recurring over time. For 
patients meeting diagnostic criteria for FAPS who exhibit a longstanding history of 
pain behaviors and certain psychosocial correlates, the clinical evaluation typically 
fails  to  disclose  any other  specific  medical  etiology to  explain  the  illness.  In  the 
absence  of  alarm  features  common  to  the  functional  gastrointestinal  disorders, 
conservative efforts should be taken to exclude other medical conditions in a cost-
effective manner. 
Questions  for  appraising  clinical  features  of  FAPS  while  identifying  key  psychosocial 
contributors 
1. What is the patient’s life history of illness?
2. Why is the patient presenting now for medical care?
3. Is there a history of traumatic life events?
4. What is the patient’s understanding of the illness?
5. What is the impact of the pain on activities and quality 
of life?
6. Is there an associated psychiatric diagnosis?
7. What is role of family or culture?
8. What  are  the patient’s  psychosocial  impairments  and 
resources?
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Physiological features 
              The observations that symptoms are reported as constant and unrelated to 
physiological events along with the common responsiveness of FAPS symptoms to 
low-dose tricyclic antidepressants point toward central neuropathic pain as a likely 
pathophysiological  process.  The  common  comorbidity  of  FAPS  with  psychiatric 
disorders  (in  particular,  anxiety,  depression,  and  somatization)  and  the  fact  that 
chronic abdominal pain is common in major depressive disorder suggest a prominent 
role  of  the  central  nervous  system  in  altering  pain  modulation  (cognitive  or 
emotional). This does not exclude the possibility that, as in other neuropathic pain 
conditions, peripheral factors play a role in initiating or perpetuating this chronic pain 
state;  scientific  evidence to  support  such a  mechanism,  however,  is  not available. 
Descending  pain  modulation  systems  (opoidergic,  serotonergic,  and  noradrenergic 
pathways)  originate  in  distinct  brainstem  regions  and  modulate  spinal  cord 
excitability. It has been speculated that patients with various chronic pain syndromes, 
including  fibromyalgia  and  FAPS,  have  compromised  ability  to  activate  such 
endogenous pain inhibition systems or exhibit an imbalance between facilitatory and 
inhibitory  systems.  Recent  studies  performed  by  using  functional  brain-imaging 
techniques identify interactions between prefrontal cortical regions, limbic regions, 
and  brainstem  regions  that  could  provide  the  neurobiological  substrate  for  the 
influence of cognitive factors on symptom perception in FAPS. Belief systems and 
coping  styles  characteristically  seen  in  FAPS  patients  are  consistent  with  the 
possibility of altered influences of cortical networks (including prefrontal and parietal 
cortical regions) on limbic and pain modulation circuits.47
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Psychological features 
                FAPS shows a close relationship with a variety of psychiatric and 
psychological conditions. Clinical evidence suggests that there is a strong association 
of aversive early life events and certain types of psychosocial stressors with increased 
pain  reports  among  patients  with  functional  gastrointestinal  disorders.48 The 
combination of genetic factors, vulnerability factors, and adult stress may determine 
in  part  the  effectiveness  of  endogenous  pain  modulation  systems  and  thereby 
influence  development  of  FAPS.  Population  and  patient-  based  studies  have 
confirmed the significant association between chronic abdominal pain and affective 
disorders,  especially  anxiety  and  depression.  Symptom-specific  anxiety  has  been 
proposed recently as having a more direct influence on pain than general anxiety, and 
this  construct  also  has  been  investigated  in  functional  gastrointestinal  disorders 
including abdominal pain. FAPS may be seen with other somatoform disorders (e.g., 
somatization  disorder,  conversion  disorder,  and  hypochondriasis).  In  a  study  of 
somatization disorder  identified in  a  primary-care population,  abdominal  pain was 
present in 30% of subjects and was the third most frequent somatic symptom (after 
headache and back pain).
         Pain beliefs and coping strategies are important in chronic pain and somatoform disorders and are 
significant  predictors  of  quality  of  life  impairment  and  treatment  response.  Patients  may  exhibit 
ineffective coping strategies (e.g., “catastrophizing”) or have poor social or family support. Unresolved 
losses, including onset or exacerbation of symptoms after the death of a parent or spouse, personally 
meaningful surgery (e.g., hysterectomy and ostomy), or interference with the outcome of a pregnancy 
(abortion, stillbirth), are common in FAPS. Histories of sexual and physical abuse are prevalent, but 
elevated rates are not specific for this diagnosis. These histories predict poorer health status, medical 
refractoriness, increased diagnostic and therapeutic procedures, and more frequent health care visits. 
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Such trauma may increase awareness of bodily sensations, although visceral pain thresholds are not 
reduced. 
Treatment 
In  contrast  to  IBS, treatment  recommendations for  patients  with FAPS are 
empirical and not based on results from well-designed clinical trials. The accepted 
basis  for clinical  management of FAPS relies on establishing an effective patient- 
physician relationship,  following a  general  treatment  approach,  and offering more 
specific  management  that  often  encompasses  a  combination  of  treatment  options. 
Factors that contribute to an effective patient-physician relationship include empathy 
toward the patient, patient education, validation of the illness, reassurance, treatment 
negotiation,  and  establishment  of  reasonable  limits  in  time  and  effort.  Before 
implementing specific forms of therapy (e.g.,  antidepressants and anticonvulsants), 
the following general aspects of care should be considered: setting of treatment goals, 
helping the patient take responsibility, basing treatment on symptom severity and the 
degree of disability, and referring to a mental health care professional or, if available, 
to a multidisciplinary pain treatment center in selected patients, particularly those with 
refractory  symptoms.  Unfortunately,  establishing  a  diagnosis,  an  effective  patient 
physician  relationship,  and  a  general  treatment  plan  often  is  overlooked.  Lack of 
confident  diagnosis,  non  therapeutic  physician  attitudes,  excessive  testing  and 
treatment (including unnecessary surgery), and patient cognitions often contribute to a 
cycle of ineffective, costly management.49 
                     Pharmacological therapies. Antidepressants, particularly tricyclic 
antidepressants (TCAs) in low daily dosages, are helpful in treating chronic pain and 
other painful functional gastrointestinal disorders, such as IBS, and may be useful for 
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the treatment of FAPS for both direct pain management effects and antidepressant 
effects.  However,  evidence  from controlled  clinical  trials  for  the  effectiveness  of 
antidepressants in FAPS or superiority of any 1 agent or antidepressant class in this 
disorder is not available. In other chronic pain conditions, trials with TCAs generally 
have been more successful than those using selective serotonin-reuptake inhibitors. 
Newer agents with combined serotonin and nor epinephrine reuptake activity (SNRIs, 
such as venlafaxine and duloxetine) have recognized pain- reducing effects in some 
somatic  pain  conditions  and may prove  useful  in  FAPS.  Both  selective  serotonin 
reuptake inhibitors and SNRIs may be useful in the patient with comorbid depression 
or anxiety. Most analgesics (e.g., aspirin and nonsteroidal anti-inflammatory drugs) 
offer little benefit, possibly because their actions primarily are peripheral in location. 
Narcotic  analgesics  should be avoided because  of  the likelihood of  addiction  and 
possibility  of  narcotic  bowel  syndromes,  such  as  chronic  neuropathic  pain,  as 
alternatives to TCAs with fewer side effects. The most studied have been gabapentin, 
carbamazepine,  and  lamotrigine.  They  have  not  been  examined  specifically  in 
abdominal  pain  disorders  or  FAPS,  although there  is  a  rationale  and evidence  of 
efficacy in chronic pain management remains limited despite rather widespread use. 
These agents are  relatively safe  and non-habituating,  also may interrupt  the cycle 
between pain and depression50 and might  prove beneficial  as adjunctive agents in 
some refractory patients, although direct evidence is lacking. In summary, anecdotal 
reports and observed benefits of some compounds in other chronic pain conditions 
provide the basis for pharmacological treatment of FAPS not scientific evidence from 
controlled clinical trials.
         Psychological therapy.  No psychological treatment study specifically has 
targeted  adult  FAPS.  However,  studies  in  other  painful  functional  gastrointestinal 
disorders  and  non-gastrointestinal  pain  conditions  suggest  that  psychological 
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treatments would be beneficial.  Interventions of potential benefit include cognitive 
behavioral therapy, dynamic or interpersonal psychotherapy, hypnotherapy, and stress 
management.  Referral  to  pain  treatment  centers  for  multidisciplinary  treatment 
programs  may be  the  most  efficient  method  of  treating  disability  from refractory 
chronic pain. Although the various psychological treatments described earlier have 
been shown to improve mood, coping, quality of life, and health care costs, they have 
less demonstrable impact on specific visceral or somatic symptoms, suggesting that 
their  best  use  may be  in  combination  with  symptomatic  treatment.  Psychological 
treatment may be most accepted if presented as a parallel intervention with ongoing 
medical care, a means for managing pain, and an attempt to reduce psychological 
distress from the symptoms.
         Complementary therapies. Patients with chronic pain disorders, including 
FAPS,  commonly  use  complementary  and  alternative  therapies,  such  as  spinal 
manipulation,51 massage,52 and acupuncture53 although data supporting their use are 
limited.  Few  reports  have  described  the  use  of  transcutaneous  electrical  nerve 
stimulation  in  patients  with  FAPS,  and  uncontrolled  results  are  indeterminant. 
Although uncontrolled studies suggest a significant diagnostic and therapeutic benefit 
of laparoscopy with intended adhesiolysis in patients  with chronic abdominal pain 
tentatively attributed to adhesions from prior surgical procedures, the outcome may be 
placebo related and unsuspected diagnoses are rare. A blinded, randomized trial of 
100 patients undergoing either laparoscopic adhesiolysis  or diagnostic laparoscopy 
alone  found  no  advantage  to  adhesiolysis.  This  study  also  reported  a  significant 
improvement in chronic abdominal pain over 6 months whether laparoscopy alone or 
laparoscopic adhesiolysis  were performed, suggesting spontaneous improvement in 
these patients over time. 
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MATERIALS AND METHODS
All  patients  who  attended  the  Gastroenterology  Outpatient  clinic  of  the  Stanley  Medical 
College  Hospital  between  July  2006  and  December  2006  for  a  lower  gastrointestinal  complaint 
requiring  a  colonoscopy for  evaluation  were  included  in  the  study.  At  their  first  visit,  data  was 
collected in a structured proforma (annexure I) incorporating the bowel symptom questionnaire and 
were offered a full diagnostic workup, as considered appropriate based on the presenting symptoms. 
The data recorded included the age, gender, educational status (illiterate, primary, middle, high school 
and  college),  duration  of  symptoms,  clinical  symptomatology,  relevant  findings  on  clinical 
examination,  basic  laboratory data,  imaging  and  findings  at  colonoscopy.  Questionnaire data  were 
collected prospectively in the above mentioned time period. Data were then retrospectively audited. 
Ethics committee approval was obtained prior to the initiation of the study.
All  patients of functional  bowel disorders (FBS) and functional  abdominal pain syndrome 
(FAPS) were diagnosed based on the history, physical examination and appropriate negative diagnostic 
tests, including lower endoscopy. All patients underwent a full-length colonoscopy. In those patients in 
whom the caecum and terminal ileum could not be intubated were excluded from the analysis. Also 
patients were excluded if they had not completed a full diagnostic workup or had a colonoscopy for an 
indication other than a lower GI disorder. Alarm features, gastrointestinal symptoms, and factors that 
might indicate an organic disease on laboratory evaluation were considered for analysis. Patients were 
finally grouped into those having a functional disorder (Group I) and those with an organic disorder 
(Group II). The ability of the symptoms, alarm features and abnormalities on laboratory investigations 
to predict an underlying organic disease was then assessed by statistical analysis.
STATISTICAL ANALYSIS
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Prevalence estimates were reported for all symptoms and for all disease risk 
factors,  stratified  by  diagnostic  group  membership; univariate  associations  were 
assessed  using  Pearson’s 2 test.  Comparisons  were performed between functional 
bowel  disorders  and organic  illnesses  of  the lower gastrointestinal  tract.  Student’s 
independent “t test” was used for quantitative data.  
Logistic regression was used to assess the value of alarm features  in discriminating functional 
disorders from organic disease Alarm features were entered into a regression model, and backward 
stepwise elimination was used to identify the best subset of symptoms that predicted a diagnosis of 
organic disease. For significant risk factors identified on univariate and multivariate analysis, odds ratio 
was calculated and their 95% confidence intervals were recorded.  P values of < 0.05, were considered 
significant.
RESULTS
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A total of 104 patients underwent colonoscopy during the study period. Twenty one patients 
were excluded in accordance with the following criteria: 11 had functional illnesses that did not meet 
the ROME III criteria for functional bowel disorders or functional abdominal pain syndrome, 5 had an 
incomplete colonoscopy due to inadequate preparation or technical difficulty, 5 had not undergone all 
diagnostic procedures that were considered necessary.
Fig 1. Gender distribution
71%
29%
Men
Women
In total, 83 patients entered the study following the inclusion and exclusion 
criteria. There were 59 (71%) men and 24 (29%) women in the study group (Fig 1). 
Mean patient age was 44 + 15.32. Men were older than women 45.83 + 15.01 Vs 39.5 
+ 15.47, though statistically not significant (p=0.09). 
Of the 83 patients, 54 (65.1%) patients had a functional disorder (Group I) and 29 (34.9%) had 
an organic lower GI illness (Group II). The functional LGI disorders that were diagnosed were IBS – C 
in 8 (14.8%), IBS – D in 12 (22.2%), functional constipation in 16 (29.6%), functional diarrhea in 4 
(7.4%) and functional abdominal pain syndrome in 14 (25.9%) patients.
 The distribution of LGI organic diagnoses were Colorectal malignancy in 5 
(17.3%),  lymphoma  in  1  (3.4%),  benign  polyp  in  4  (13.8%),  tuberculosis  in  4 
(13.8%), ulcerative colitis in 2 (6.9%), crohn’s disease in 1 (3.4 %), perianal disease 
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in 11 (40%) and systemic illness causing lower GI symptoms in 1 (3.4%) patient. 
Table 1. Age distribution
Mean age > 40 yrs > 50 yrs > 60 yrs
Group I (54) 44.11 + 15.5 30 26 12
Group II 
(29)
43.79 + 15.3 17 11 4
p value 0.93 0.78 0.37 0.35
The mean age of patients in group I was 44.11 + 15.5 years and for those in 
group  II  was  43.8  + 15.3  years;  the  differences  were  not  statistically  significant 
(p=0.93). Sub stratification of the study group into  > 40 yrs,  > 50 yrs and  > 60 yrs 
also did not reveal any significant differences between the two groups. (Table 1)
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Table 2. Gender ratio and literacy status of the study population
Group I
No. (%)
Group II
No. (%)
P value
Gender
 
Male 40 (74.1) 19 (65.5)
Female 14 (25.9) 10 (34.5) 0.41 
Education
 
 
 
 
Illiterate 12 (22.2) 5 (17.2)
Primary 8 (14.8) 7 (24.1)
Middle 10 (18.5) 10 (34.5)
High school 20 (37) 6 (20.7)
College
4 (7.4) 1 (3.4)
0.26 
Both groups of disorders were male predominant and the ratios were 2.9 and 
1.9 for groups I and II respectively, with differences between the two groups being 
statistically insignificant (p = 0.41). The differences in literacy status between the two 
groups were also not significant (p = 0.26). (Table 2)
The mean duration of symptoms in group I was 95.56 + 193.58 weeks and in 
group II was 24.28 + 37.34 weeks (p = 0.01). 
49
Table 3. Significance of symptoms in diagnosis
Group I
No. (%)
Group II
No. (%)
p 
value
Odds ratio
(95% CI)
Nocturnal 
symptoms
Yes 2 (3.7) 5 (17.2)
No 52 (96.3) 24 (82.8) 0.03
5.4 (1.01 - 43.8)
Blood in stools Yes 4 (7.4) 13 (44.8)
No 50 (92.6) 16 (55.2) 0.001
10.2 (26.3 – 43.7)
Mucus in stools Yes 10 (18.5) 7 (24.1)
No 44 (81.5) 22 (75.9) 0.55
-
Rectal symptoms Yes 10 (18.5) 4 (13.8)
No 44 (81.5) 25 (86.2) 0.58
-
Incomplete evacuation Yes 25 (46.3) 10 (34.5)
No 29 (53.7) 19 (65.5) 0.30
-
Mass descending PR Yes 0 (0) 4 (13.8)
No 54 (100) 25 (86.2) 0.005
-
Abdominal pain Yes 32 (59.3) 14 (48.3)
No 22 (40.7) 15 (51.7) 0.34
-
Digital evacuation Yes 6 (11.1) 5 (17.2)
No 48 (88.9) 24 (82.8) 0.43
-
Anorexia Yes 26 (48.1) 19 (65.5)
No 28 (51.9) 10 (34.5) 0.13
-
Weight loss Yes 2 (3.7) 11 (37.9)
No 52 (96.3) 18 (62.1) 0.001
15.9 (2.9 – 115.6)
Tuberculosis in the past Yes 2 (3.7) 4 (13.8)
No 52 (96.3) 25 (86.2) 0..09
-
Comorbid illness Yes 10 (18.5) 10 (34.5)
No 44 (81.5) 19 (65.5) 0.10
-
Surgery Yes 18 (33.3) 12 (41.4)
No 36 (66.7) 17 (58.6) 0.47S
-
Family H/O Yes 2 (3.7) 1 (3.4)
No 52 (96.3) 28 (96.6) 0.95
-
UGI symptoms Yes 18 (33.3) 6 (20.7)
No 36 (66.7) 23 (79.3) 0.22
-
The clinical symptomatologies that were statistically significant on univariate 
analysis (Table 3) were presence of nocturnal symptoms (p = 0.03), blood in stools (p 
=  0.001),  mass  descending  per  rectum (p  =  0.005)  and  weight  loss  (p  =  0.001). 
Symptoms like mucus in stools,  rectal  symptoms, sense of incomplete evacuation, 
presence,  character  or  location  of  pain,  digital  evacuation  of  stools,  anorexia, 
comorbid illness,  abdominal  surgery or  tuberculosis  in  the  past,  family history of 
cancer  or  the  presence  of  associated  upper  GI  symptoms  were  not  statistically 
significant  to  differentiate  an organic  from a functional  LGI disease.  None of the 
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symptoms evaluated favored the diagnosis of a functional LGI disorder by inclusion.
Table 4. Significance of abnormalities on clinical examination and investigations
Group I
No. (%)
Group II
No. (%) p value
Odds ratio
(95% CI)
Anemia
 
Yes 4 (7.4) 11 (37.9)
No 50 (92.6) 18 (62.1) 0.001   
7.6 (1.9 – 33.2)
Lymphadenopathy
 
Yes 0 (0) 1 (3.4)
No 54 (100) 28 (96.6) 0.17 
-
Mass abdomen
 
Yes 0 (0) 2 (6.9)
No 54 (100) 27 (93.1) 0.05
-
Tenderness Yes 8 (14.8) 10 (34.5)
No 46 (85.2) 19 (65.5) 0.04
3.03 (1.01 – 10.1)
Per rectal exam.
 
Yes 0 (0) 3 (10.3)
No 54 (100) 26 (89.7) 0.02 
-
Low hemoglobin
 
Yes 10 (18.5) 16 (55.2)
No 44 (81.5) 13 (44.8) 0.001 
3.6 (1.2 – 11.1)
Total Count
 
Yes 1 (1.9) 2 (6.9)
No 53 (98.1) 27 (93.1) 0.57 
-
Raised ESR
 
Yes 8 (14.8) 10 (34.5)
No 46 (85.2) 19 (65.5) 0.04 
3.03 (1.01 – 10.1)
Stool occult blood
 
Yes 0 (0) 4 (22.2)
No 52 (100) 14 (77.8) 0.001 
-
High blood sugar Yes 2 (3.7) 2 (6.9)
No 52 (96.3) 27 (93.1) 0.91
-
Low total protein
 
Yes 0 (0) 4 (13.8)
No 54 (100) 25 (86.2) 0.005 
-
Low S. Albumin
 
Yes 2 (3.7) 5 (17.2)
No 52 (96.3) 24 (82.8) 0.03 
5.4 (1.01 – 43.8)
Abnormality on USG Yes 0 (0) 3 (10.3)
No 54 (100) 26 (89.7) 0.02 
-
Abnormal colonoscopy Yes 0 (0) 28 (82.8)
No 54 (100) 1 (3.4) 0.001
-
The presence of anemia (p = 0.01), mass abdomen (p = 0.05) and a positive finding on per 
rectal examination (p = 0.02) suggested an organic pathology. Moreover a low hemoglobin (p = 0.001), 
an elevated ESR (p = 0.04), stool occult blood positivity (p = 0.001), low total protein (p = 0.005), 
albumin (p = 0.03), abnormality on ultrasonogram (p=0.02) and colonoscopy (p=0.001) also suggested 
the probability of diagnosing an organic LGI disease with statistical significance. The total count (p = 
0.57)  and  blood  sugar  (p  =  0.91)  were  not  significant  variables.  
(Table 4)
Table 5. Multivariate logistic regression using backward elimination
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Variables p value Odds ratio 95% CI
Duration of illness 0.01 1.03 1.01 – 1.05
Blood in stools .021 5.5 1.29 – 25.0
Weight loss .001 17.5 1.33 - 90.9
Tenderness .004 11.1 4.45 – 41.6
Anemia 0.007 6.25 1.66 –23.8
Mass 0.01 4.33 1.33 - 19.4
Abnormal colonoscopy 0.02 3.22 1.12 – 8.6
(Variable(s) entered on step 1: nocturnal symptoms, blood in stools, rectal symptoms, mass 
descending per rectum, anorexia, weight loss, tuberculosis, comorbid illness, family history, anemia, 
lymphadenopathy,  mass  abdomen,  per  rectal  examination,  abnormality  on  ultrasonogram  and 
colonoscopy)
The variables that showed statistical significance in differentiating an organic 
from a functional lower GI disease on multivariate analysis (Table 5) were passage of 
blood in stools (p = 0.02), weight loss (p = 0.01), abdominal tenderness (p = 0.004), 
anemia  (p  = 0.007),  presence  of  mass  abdomen (p  =  0.01)  and abnormalities  on 
colonoscopy (p=0.02).
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Table 6. Sensitivity, Specificity, PPV, NPV & Efficacy of Clinical 
Vs final diagnosis
95% Confidence interval
Sensitivity 69% 54% to 80%
Specificity 62% 42% to 79%
Positive predictive value 77% 62% to 88%
Negative predictive value 51% 34% to 69%
Efficacy 66% 55% to 76%
The clinical  differentiation between functional  and organic  LGI disease on 
clinical and laboratory investigations had a sensitivity of 69%, specificity of 62%, 
positive predictive value of 77%, negative predictive value of 51%, efficacy of 66% 
with the kappa statistics showing a fair agreement (k=0.29, p=0.007) (Table 6)
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DISCUSSION
The presence of alarm features in patients with symptoms suggestive of IBS 
should shift the physician’s differential diagnosis towards structural or inflammatory 
conditions based on the present results. However, the present data demonstrate that the 
actual diagnostic  yield of  most  of the alarm features  assessed is  limited when the 
ROME III criteria are taken as the basis of the diagnosis.  In the present study certain 
alarm features, including signs of rectal blood loss, mass abdomen and weight loss, 
had  some  value  in  discriminating functional  from  lower  gastrointestinal  organic 
disease.  Although  only  three  of  the  evaluated  alarm features  were  significant 
discriminators of functional from organic lower gastrointestinal diseases, the present 
results suggest that a symptom based diagnosis, combined with a limited amount of 
alarm feature  data,  improve  the  diagnostic  yield  of  the  history, as  captured  by a 
questionnaire. 
This study detected that functional constipation was more common than IBS 
per se, which is the more predominant form of functional bowel disorder reported 
from other countries. This adds to the contention that pain is not a major component 
of functional disorders in this population. The finding that literacy status does not 
influence the diagnosis may be due to a bias that this center caters to the health needs 
of  a  population  with  low literacy  and  socioeconomic  status,  free  of  cost.  Larger 
studies  with more  representative  population  should  be incorporated  to  clarify this 
issue.
In a study by Hammer et al54 age 50 years at symptom onset and blood on the 
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toilet  paper  emerged as  alarm  features  that  discriminated  organic  lower 
gastrointestinal illness from IBS. A diagnosis of IBS was typically associated with 
female sex,  pain on six or more occasions in  the previous year, pain that  radiated 
outside of the abdomen, and pain associated with looser bowel motions. In the present 
study  the  presence  of  nocturnal  symptoms,  blood  in  stools,  mass  descending  per 
rectum  and  weight  loss  helped  differentiation  of  functional  LGI  disorders  from 
organic diseases. However, in contrast to other studies,54 age of onset of symptoms 
was not a significant factor. Moreover, none of the symptoms evaluated, or female 
gender favored the diagnosis of a functional LGI disorder by inclusion. In contrast to 
several other studies54 men were affected by functional LGI disorders than women, 
though  the  differences  were  not  statistically  significant.  This  corroborates  with  a 
previous report from this center55 wherein it was found that 70.3% of patients with 
IBS were men and 29.7% were women. 
The development of criteria to positively diagnose functional bowel disorders has evolved 
since the Manning criteria4 were first described. Kruis et al5 developed a different scoring system that 
included key gastrointestinal symptoms but also incorporated the results from a physical examination 
and basic laboratory tests.  As both the Manning criteria and the Kruis scoring system have shown 
unsatisfactory sensitivity and the Kruis scoring system has proved to be too cumbersome for clinical 
practice, there have been a number of adaptations, with the Rome III symptom based criteria being the 
most recent and widely accepted. In a study by Vanner et al10 of the Rome I criteria, found a sensitivity 
of  only 35% in diagnosing IBS.  However, when alarm symptoms were included in the diagnostic 
workup, sensitivity increased to 63% with a specificity of 100%. In a prospective arm of the same 
study, the Rome I criteria in combination with alarm symptoms had a positive predictive value of 98% 
in diagnosing IBS. 
A  previous  study56 evaluated  whether  extensive  diagnostic  testing might 
improve  the  diagnostic  yield  in  IBS.  Laboratory  tests, including  erythrocyte 
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sedimentation rate as well as stool tests for microorganisms, provided no increased 
diagnostic yield in the study. The authors concluded that these diagnostic tests should 
not  be  part  of  the  routine  evaluation  for  IBS  unless there  is  a  specific  clinical 
indication from the history or physical examination. The present study assessed the 
value of laboratory tests in the diagnostic workup of functional bowel disorders. Thirty 
seven patients  with a functional LGI disease and 18 patients  with an organic LGI 
disease were correctly diagnosed clinically while 17 patients in the functional group 
and 11 patients in the organic group were misclassified as having an organic LGI 
disease and functional LGI disease respectively. Thus alarm features in combination 
with the basic laboratory evaluation has a sensitivity of 69%, specificity of 62% and 
positive predictive value of 77% and suggest that laboratory tests though useful do not 
have sufficient sensitivity or specificity to diagnose or refute the possibility of an 
underlying  organic  illness.  Moreover,  addition  of  colonoscopy  to  the  diagnostic 
algorithm, a sensitivity and specificity of 100% was obtained, thereby indicating that 
it  would be appropriate  to perform a colonoscopy in  all  patients  with a lower GI 
symptom to exclude an underlying organic disease and to allay patient anxiety. 
Newer tests to document colonic inflammation may be useful; Tibble et al57 showed that faecal 
calprotectin  was  of  value  in  the differential  diagnosis  of  functional  versus  organic  gastrointestinal 
disorders  in  a  tertiary  referral  center  although  the  authors did  not  include  alarm features  in  their 
evaluation of intestinal disease.  However until  the discovery of a test specific for functional bowel 
disorder/ functional abdominal pain syndrome, it would remain a diagnosis of exclusion. 
 The present study had fewer references during the study period resulting in fewer organic 
diseases in the sample and less cancers than would have been ideal for analysis. Only 34.9% of patients 
had a diagnosis of  organic disease while  the rest  had a functional  bowel  disorder.  However, most 
patients  with  organic  disease  had  symptoms that  were  judged to  be  most  likely explained  by the 
56
underlying condition. Moreover all known alarm features were evaluated and the chances that a few of 
the alarm symptoms that have not yet been identified could have been inadvertently excluded; the value 
of  these  other  alarm symptoms  cannot  be  determined  here.  Confirmation  of  the  results  that  were 
obtained with the functional LGI disorder group will require another study with a larger group of such 
patients. 
In  conclusion,  the  Rome criteria  have  standardised  the  field of  functional  gastrointestinal 
disorders and promoted new clinical and epidemiological research. The present study, as well as those 
of Vanner et al10 and Hammer et al,54 allow to conclude that the Rome criteria and Manning criteria 
identify fewer patients as having functional GI disorders than are diagnosed by clinicians, suggesting a 
need to adjust the current diagnostic guidelines. However, it may be appropriate that the Rome criteria 
for functional bowel disorders and functional abdominal pain syndrome be expanded to include key 
alarm features, basic investigations and colonoscopy. 
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SUMMARY AND CONCLUSIONS
1. The incidence of organic and functional disorders in patients presenting with 
lower gastrointestinal complaints are 34.9% and 65.1% respectively.
2. The commonest organic disorder to be diagnosed was perianal disease (40%) 
and the commonest functional disorder was functional constipation (29.6%).
3. No significant  differences  in  the  mean age  or  age  group distribution  were 
discernible between the two groups of disorders
4. There were no significant differences in the gender ratio or educational status 
of patients in the two groups
5. The clinical symptoms that were helpful in distinguishing an organic illness 
from a functional disorder were the presence of nocturnal symptoms, blood in 
stools, mass descending per rectum and weight loss. None of the symptoms 
evaluated favored the diagnosis of a functional LGI disorder by inclusion.
6. The  presence  of  anemia,  mass  abdomen  and  abnormalities  on  per  rectal 
examination suggested an organic disease
7. The laboratory investigations  that  differentiated an organic  from functional 
disease include a low hemoglobin, elevated ESR, stool occult blood positivity, 
low  serum  proteins  and  albumin,  abnormalities  on  ultrasonography  and 
colonoscopy with terminal ileoscopy 
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8. The clinical differentiation between functional and organic LGI disease had a 
sensitivity  of  69%,  specificity  of  62%,  positive  predictive  value  of  77%, 
negative predictive value of 51%, efficacy of 66% with fair  agreement  on 
Kappa statistics.
9. It may be appropriate that the Rome criteria for functional bowel disorders and 
functional  abdominal  pain  syndrome  be  expanded  to  include  key alarm 
features, basic investigations and colonoscopy.  
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                                                  ANNEXURE  - I
THE OUTCOME OF ALARM SYMPTOMS AND COLONOSCOPY IN 
FUNCTIONAL BOWEL DISORDERS AND FUNCTIONAL ABDOMINAL 
PAIN SYNDROME 
Name: Age/sex MGE No. SGE No.
Address: Education:
Clinical diagnosis: Provisional diagnosis:
Colonoscopy diagnosis:
Clinical parameter Status Duration
Bowel frequency
     Day/ Night
Consistency Hard/ Normal/ Semi formed/ Liquid
Blood in stools
Mucus in stools
Incomplete evacuation
Tenesmus
Painful defaecation
Mass descending PR
Abdominal pain
    Character
    Location
Intestinal obstruction
Digital evacuation
Intolerance to milk
Anorexia
Weight loss
Mass abdomen
Symptoms of anemia
Fever
Diabetes mellitus
Hypertension
Ischemic heart disease
Tuberculosis
Drugs (specify)
Surgery (specify)
Family history Ca colon/ Polyp/ IBD/ TB 
Associated symptoms
     Dyspepsia Ulcer/ reflux/ dysmotility
     Others (specify)
     Cardiovascular
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     Respiratory
     Neurological
     Others (specify)
Clinical examination Status
Anemia
Clubbing
Edema
Lymphadenopathy/ site
Mucocutaneous manifestations (specify)
Weight/ Height/ BMI
Pulse
Blood pressure
Abdomen
   Tenderness - site
   VIP
   Scar
   Mass
   Others (specify)
Per rectum
Investigations Report
Hemoglobin
Total Count
Differential count
ESR
Peripheral smear
Stool
   Ova
   Cyst
   Occult blood
Blood sugar
TSH
Total protein
Albumin/ globulin
LDH
Others (specify)
CXR
AXR
USG abdomen:
CT/ MRI abdomen:
Barium meal follow through/ Barium enema:
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Colonoscopy:
Histopathology:
Interventions: Surgical/ endoscopic (specify with details)
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